Best Peptides for Libido: Evidence-Backed Options

PT-141 (Bremelanotide) is the FDA-approved peptide for libido — specifically premenopausal female hypoactive sexual desire disorder. Melanotan II shares the melanocortin-receptor mechanism and produces similar libido effects in research-use settings. Kisspeptin and Oxytocin work via different pathways with smaller direct-libido evidence. HCG and Gonadorelin support sexual function indirectly via testosterone-axis preservation. This ranking covers what each does and which fits which pattern.

For the bare hub see /peptides/category/sexual-health.

Quick verdict table

	Mechanism	Best for	Approval
PT-141 (Bremelanotide)	Melanocortin receptor agonist	On-demand libido in HSDD	FDA-approved (Vyleesi)
Melanotan II	Melanocortin receptor agonist	Libido + tanning	Research-use
Kisspeptin	GnRH-axis upstream signal	HPG-axis libido modulation	Research-use; investigational
Oxytocin	Pair-bonding / arousal	Relationship-context libido	Approved for other indications
HCG	LH-mimetic; testosterone preservation	Libido during testosterone-suppressing protocols	FDA-approved
Gonadorelin	GnRH analog	HPG-axis support	Approved for diagnostics + fertility

The major options

1. PT-141 (Bremelanotide)

The FDA-approved peptide for libido (Vyleesi). Indication: premenopausal female hypoactive sexual desire disorder (HSDD). Mechanism: melanocortin receptor agonism (MC3R / MC4R) in the central nervous system.

Pattern: Subcutaneous injection on-demand at least 45 minutes before anticipated sexual activity. 1.75 mg per dose. Not more than 8 doses per month per the label.

Side effects: Nausea (the dose-limiting factor — ~40% of trial participants), flushing, headache, transient blood-pressure elevation. Contraindicated in uncontrolled hypertension.

Off-label use for male sexual function is widespread; some clinical evidence supports it but it's not FDA-approved for that indication.

PT-141 research profile.

2. Melanotan II

Same melanocortin-receptor mechanism as PT-141 but a broader agonist profile. Produces libido enhancement alongside its primary tanning effect. Research-use only.

Pattern: Variable; typically 250–500 mcg SC during loading, with on-demand dosing for sexual use.

Side effects: Nausea, flushing, persistent darkening of skin and moles (the primary effect of the compound), priapism rarely, BP elevation. Mole monitoring recommended.

Melanotan II research profile.

3. Kisspeptin

Neuropeptide that drives GnRH release from the hypothalamus — the upstream regulator of the entire HPG axis. Newer research has shown direct sexual-arousal effects via central pathways independent of the HPG effect.

Pattern: Investigational. Small clinical trials use single doses for arousal endpoints.

Kisspeptin research profile.

4. Oxytocin

The pair-bonding / social-attachment hormone. Effects on libido are real but contextual — most pronounced in relationship-context arousal rather than general libido. Intranasal use has more clinical research than injected use.

Pattern: Intranasal 24–40 IU before social/sexual context; injected protocols vary.

Oxytocin research profile.

5. HCG

LH-mimetic; maintains testicular size and testosterone production during testosterone-suppressing protocols (TRT, PCT, fertility preservation). Used to support libido as a downstream effect of preserved testosterone production rather than as a direct libido agent.

Pattern: 250–500 IU SC 2–3× weekly during T-suppression protocols.

HCG research profile.

6. Gonadorelin

GnRH analog. Stimulates the entire HPG axis (LH + FSH + downstream). Similar role to HCG in TRT-context fertility preservation but works one step upstream.

Gonadorelin research profile.

Indication-to-peptide mapping

• Premenopausal female HSDD (FDA-approved indication): PT-141 (Vyleesi).
• Male erectile dysfunction: PDE5 inhibitors (sildenafil/tadalafil) remain first-line; PT-141 off-label is an option after PDE5 inhibitors are tried.
• Male HSDD-equivalent (low libido without ED): PT-141 off-label; first investigate testosterone, thyroid, depression, relationship factors.
• Tanning + libido combined goal: Melanotan II (research-use only; mole monitoring required).
• Libido decline during TRT: Add HCG or Gonadorelin to preserve testicular function and intratesticular testosterone.
• Relationship-context arousal / bonding: Oxytocin (intranasal, contextual use).

What this category won't do

• Fix mechanical erectile dysfunction (vascular, neurological, structural causes — peptides don't address these).
• Substitute for treating underlying depression, relationship distress, or medication side effects.
• Replace testosterone replacement therapy when the underlying issue is documented hypogonadism.

Safety frame

• PT-141: Nausea is the dose-limiting side effect. Contraindicated in uncontrolled hypertension.
• Melanotan II: Mole monitoring; risk of pigmentation changes; rare priapism.
• Oxytocin: Generally well-tolerated; intranasal route avoids most concerns.
• HCG / Gonadorelin / Kisspeptin: Generally well-tolerated; require monitoring in context of broader hormonal protocol.

See are peptides safe?, peptide side effects.

Where to go from here

• /peptides/category/sexual-health — ranked hub.
• Per-peptide profiles linked above.
• Operational: calculator, how to inject.
• Safety + clinical frame: are peptides safe?, peptide therapy.

This is informational, not medical advice.